- A first report of pooled safety data in Orencia SC & IV formulations based on the exposure of more than 6,000 patients, which examines the incidence rates and events reported with long-term Orencia treatment.
- Long-term safety and efficacy of Orencia IV in pediatric patients 6 years of age and older with moderately to severely active polyarticular JIA, with results including up to seven years of follow-up.
- Analysis of the onset of treatment response and magnitude of efficacy improvement with Orencia SC over six months, with or without an intravenous Orencia loading dose.
|Session Date, Time, Location (all at Walter E. Washington Convention Center)||Presentation Title||Lead Author|
|Sunday, November 119:00 AM – 6:00 PM Location: Poster Hall (Hall B)||Subcutaneous Abatacept: Long-Term Data From the ACQUIRE Trial||M. Genovese Palo Alto, CA|
|Sunday, November 119:00 AM – 6:00 PM Location: Poster Hall (Hall B)||Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the ACTION Study||H. Nüßlein Erlangen, Germany|
|Sunday, November 114:30 PM – 6:00 PM Oral Presentation time: 5:15 PM – 5:30 PM Location: Salon B||Assessment of OMERACT Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate||M.A. D'Agostino Boulogne-Billancourt, France|
|Sunday, November 114:30 PM – 6:00 PM Oral presentation time: 5:30 PM – 5:45 PM Location: Salon B||The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate||M.A. D'Agostino Boulogne-Billancourt, France|
|Monday, November 129:00 AM – 6:00 PM Location: Poster Hall (Hall B)||Effects of SC Abatacept or Adalimumab on Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results from the AMPLE Trial||R. Fleischmann, Dallas, TX|
|Monday, November 129:00 AM – 6:00 PM Location: Poster Hall (Hall B)||Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results from the AMPLE Trial||R. Fleischmann, Dallas, TX|
|Monday, November 124:30 PM – 6:00 PM Presentation time: 5:15 PM – 5:30 PM Location: 207 A||Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up||D. Lovell Cincinnati, OH|
|Monday, November 124:30 PM – 6:00 PM Presentation time: 4:45 PM – 5:00 PM Location: Hall E||Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data||M. Genovese Palo Alto, CA|
|Tuesday, November 1311:00 AM – 12:30 PM Presentation time: 11:00 AM – 11:15 AM Location: Hall E||Subcutaneous Abatacept versus Adalimumab in the Treatment of Rheumatoid Arthritis: 1 Year Results from the AMPLE Trial||M. Weinblatt Boston, MA|
|Tuesday, November 134:30 PM – 6:00 PM Presentation time: 5:00 PM – 5:15 PM Location: Hall E||Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose||M. Schiff Denver, CO|
About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews. Orencia is a registered trademark of Bristol-Myers Squibb Company. All other trademarks are property of their respective owners.